Ejso最新文献

{"title":"Reply to: Enhancing vulvar cancer care: Integrating biomarkers and AI for better outcomes","authors":"Mario Preti, Luigino Dal Maso, Stefano Guzzinati, Lauro Bucchi","doi":"10.1016/j.ejso.2024.108775","DOIUrl":"10.1016/j.ejso.2024.108775","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 3","pages":"Article 108775"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advert 2025 BASO Annual Scientific Conference","authors":"","doi":"10.1016/j.ejso.2025.109733","DOIUrl":"10.1016/j.ejso.2025.109733","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 3","pages":"Article 109733"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IBC: Filler advert REAXYS","authors":"","doi":"10.1016/S0748-7983(25)00094-0","DOIUrl":"10.1016/S0748-7983(25)00094-0","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 3","pages":"Article 109666"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascularized reconstruction following extremity sarcoma resection – More than just a means to close a wound","authors":"Yannick Albert J. Hoftiezer, Santiago A. Lozano-Calderón, H.W.B. Schreuder Bart, Dietmar J.O. Ulrich, E.P.A. van der Heijden Brigitte","doi":"10.1016/j.ejso.2024.108537","DOIUrl":"10.1016/j.ejso.2024.108537","url":null,"abstract":"","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 3","pages":"Article 108537"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: A population-based study","authors":"Xingrong Liu ,&nbsp;Louise Eriksson Bergman ,&nbsp;Caroline Boman ,&nbsp;Theodoros Foukakis ,&nbsp;Alexios Matikas","doi":"10.1016/j.ejso.2025.109587","DOIUrl":"10.1016/j.ejso.2025.109587","url":null,"abstract":"<div><h3>Introduction</h3><div>Although neoadjuvant systemic treatment for non-metastatic breast cancer has gained ground during the past decade, there is no compelling evidence that it improves overall survival compared to primary tumor resection and adjuvant treatment. At the same time, the approach to responders to neoadjuvant treatment in the axilla is evolving.</div></div><div><h3>Materials and methods</h3><div>This is a retrospective analysis of a prospectively collected population-based registry. Patients that received neoadjuvant (n = 2126) or adjuvant chemotherapy (n = 4754) for non-metastatic breast cancer during 2007–2020 in the Stockholm-Gotland region, which comprises 25 % of the entire Swedish population, were included. Overall survival of patients treated preoperatively and postoperatively was compared using inverse probability treatment weighting and landmark analysis. The prognostic impact of change between prechemotherapy clinical to postchemotherapy pathologic nodal stage (cN/pN) in women receiving neoadjuvant treatment was investigated.</div></div><div><h3>Results</h3><div>Median follow-up was 4.93 years. There was no difference in adjusted overall survival between adjuvant (reference) and neoadjuvant treatment in the entire population (HR = 1.38, 95 % CI 0.98–1.93, p = 0.062) or in breast cancer subtypes. Patients converting from positive clinical to negative pathologic nodal stage (cN+/pN0) had improved outcomes compared to cN0/pN0 or patients with pN0 following primary surgery. These patients had a particular disease trajectory, with early peak in risk of death followed by quick and sustained decrease.</div></div><div><h3>Conclusion</h3><div>There was no difference in survival of patients treated with neoadjuvant versus adjuvant systemic therapy for non-metastatic breast cancer. Patients with cN+/pN0 have excellent prognosis and represent potential candidates for de-escalation of local and systemic treatment.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 3","pages":"Article 109587"},"PeriodicalIF":3.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142963243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroendocrine tumors of the gynecological tract: A narrative literature review.","authors":"Čelebić Aleksandar, Harasani Klejda, Miladinović Mirjana, Mandić Aljoša, Vasiljević Tijana, Drusany Starič Kristina, Radunović Vasilije, Tripac Irina, Starič Drusany Ana Karolina","doi":"10.1016/j.ejso.2025.109735","DOIUrl":"https://doi.org/10.1016/j.ejso.2025.109735","url":null,"abstract":"<p><p>Neuroendocrine neoplasms (NENs) of the gynecological tract are a rare, heterogenous and aggressive group of neoplasms, with high recurrence rates and poor prognosis. In this review we focus on NENs of the gynecological system emphasizing the classification, epidemiological and clinical characteristics of NENs across the gynecological tract (cervix, endometrium, ovary, vagina, and vulva), risk/prognostic factors, pathology and molecular biology (including actionable genomic mutations), imaging, staging and the most effective treatment modalities in the \"standard of care\" approach as well as the pipeline products. We also focused on metastatic spreading patterns of gynecological NENs. We searched for all available literature reviews, interventional studies, short series, case reports and meta-analyses published from 1990 to 2024. Deteriorated survival rate is essentially impacted by early development of lymph node, distant organ metastases and vascular propagation toward rapid extra-pelvic metastasis to the brain, liver, lung, bone marrow, lymph nodes and bones. Management of NENs needs to be customized on a case-based manner and comprises a multidisciplinary approach that involves gynecologists, surgeons, medical oncologists, radiologists, radiation oncologists, nuclear medicine specialists, pathologists, molecular biologists, qualified nurses etc. The treatment of extrapulmonary NENs arising in the female genital tract is basically extrapolated from that for small cell lung cancer. This includes, but is not limited to: surgery, chemotherapy, radiotherapy, peptide receptor radionuclide therapy, somatostatin analogs, and immunotherapy as well as investigational drugs in rare prospective clinical trials. Establishing modern therapeutic thesaurus is conditioned by the existence of well-designed clinical trials targeting a tumor's genomic profile and the incorporation of these data into the actual treatment landscape.</p>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":" ","pages":"109735"},"PeriodicalIF":3.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous versus delayed resection of synchronous colorectal liver metastases: A systematic review and meta-analysis","authors":"Adil S. Lakha ,&nbsp;Vikas Sud ,&nbsp;Younis Alemour ,&nbsp;Nikhil J. Perera ,&nbsp;Hannah McGivern ,&nbsp;Carolyn Smith ,&nbsp;Alex Gordon-Weeks","doi":"10.1016/j.ejso.2025.109732","DOIUrl":"10.1016/j.ejso.2025.109732","url":null,"abstract":"<div><div>Colorectal cancer is a leading malignancy, with synchronous colorectal liver metastases (CRLM) presenting in 20 % of patients. Resection remains the gold standard treatment for CRLMs, significantly improving survival outcomes. However, the optimal timing of resection of these synchronous lesions — simultaneous versus staged — remains controversial. This systematic review and meta-analysis synthesises data exclusively from propensity-score-matched and prospective studies.</div><div>A comprehensive search of five databases identified 11 eligible studies, encompassing 2884 patients. Of these, 1453 underwent simultaneous resection, and 1431 underwent staged procedures. The primary outcome was 5-year overall survival (OS), with secondary outcomes including disease-free survival (DFS), surgical morbidity, operating time, and length of hospital stay.</div><div>Meta-analysis demonstrated no significant difference in 5-year OS between simultaneous and staged resection groups (odds ratio [OR] 1.10, 95 % CI 0.75–1.61; p = 0.83). However, simultaneous resection was associated with significantly higher 3-year DFS (OR 1.67, 95 % CI 1.28–2.17; p = 0.0001) but also increased major surgical complications (Clavien-Dindo ≥ III: OR 1.32, 95 % CI 1.03–1.68; p = 0.03).</div><div>This review highlights a lack of oncological advantage for simultaneous resection, coupled with higher morbidity, suggesting its use should be limited to select patients with low surgical risk. The findings underscore the need for well-powered, randomised trials to confirm these conclusions, as well as assess quality of life and economic outcomes, however delivering such trials in this patient cohort brings unique challenges. Until such data are available, clinical decision-making should remain individualised, guided by multidisciplinary discussion and available local expertise.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 5","pages":"Article 109732"},"PeriodicalIF":3.5,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful pregnancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal malignancies","authors":"Haggai Benvenisti ,&nbsp;Dan Assaf ,&nbsp;Eyal Mor ,&nbsp;Danielle Mor-Hadar ,&nbsp;Vahan Kepenekian ,&nbsp;Nicolas Flamey ,&nbsp;Rui Yang ,&nbsp;Douglas Zippel ,&nbsp;Almog Ben-Yaacov ,&nbsp;Yan Li ,&nbsp;Brendan Moran ,&nbsp;Olivier Glehen ,&nbsp;Aviram Nissan","doi":"10.1016/j.ejso.2025.109725","DOIUrl":"10.1016/j.ejso.2025.109725","url":null,"abstract":"<div><h3>Background</h3><div>Cytoreductive surgery (CRS) with Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) has become a successful, potentially curative, treatment option for peritoneal surface malignancies (PSM). CRS and HIPEC (CRS/HIPEC) are performed with curative intent for several intra-peritoneal pathologies. An increasing number of patients with PSM are diagnosed at a relatively young age. Given the long-term survival in some patients following CRS/HIPEC, the reproductive health of patients in this age group requires consideration.</div></div><div><h3>Methods</h3><div>Surgical oncology teams participating in the Peritoneal Surface Oncology Group International (PSOGI) were offered the opportunity to share their experience and data regarding the obstetric outcomes of female patients who had undergone CRS/HIPEC.</div></div><div><h3>Results</h3><div>Nineteen (19) patients were reported to have had a baby following CRS/HIPEC. The median interval between CRS/HIPEC and pregnancy was 37 months, and 16 patients had a normal vaginal delivery. All of the newborns were healthy, without medical issues attributed to CRS or HIPEC chemotherapy. Overall, 89 % of mothers had no evidence of disease at their last follow-up.</div></div><div><h3>Conclusion</h3><div>Successful pregnancies following CRS/HIPEC are seldom reported in the literature, and fertility preservation is not uniformly discussed. Data from this international collaboration highlights the reproductive potential in patients with PSM following CRS/HIPEC and the value of pre-operative obstetric and fertility advice and management to achieve that end.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 5","pages":"Article 109725"},"PeriodicalIF":3.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective study evaluating surgical upstaging rates in low-risk DCIS patients meeting the eligibility criteria for active surveillance trials","authors":"Jose Vila ,&nbsp;Gabriel Farante ,&nbsp;Francisco Ripoll-Orts ,&nbsp;Germana Lissidini ,&nbsp;Luca Nicosia ,&nbsp;Matteo Lazzeroni ,&nbsp;Samuele Frassoni ,&nbsp;Vincenzo Bagnardi ,&nbsp;Belén Rodríguez del Busto ,&nbsp;Bernardo Bonanni ,&nbsp;Enrico Cassano ,&nbsp;Paolo Veronesi","doi":"10.1016/j.ejso.2025.109716","DOIUrl":"10.1016/j.ejso.2025.109716","url":null,"abstract":"<div><h3>Background</h3><div>The management of small low-to-medium grade ductal carcinoma in situ (DCIS) on core biopsy remains controversial. Four international studies are currently recruiting highly selected low-risk DCIS patients to compare active surveillance ( ± hormonal treatment) versus conventional treatment. In this study, we aim to determine the upstaging rate at a tertiary center among low-risk DCIS patients meeting eligibility criteria for active surveillance trials.</div></div><div><h3>Methods</h3><div>A retrospective study was undertaken of all patients diagnosed with small (&lt;2 cm) low-medium grade DCIS patients at the European Institute of Oncology, Milan, from 2009 to 2019. All cases were classified as eligible based on the COMET, LORIS, LORD and LORETTA DCIS studies, according to their respective inclusion criteria.</div></div><div><h3>Results</h3><div>We identified 351 patients from a prospectively maintained database who were diagnosed with G1-G2 DCIS on core biopsy, with a median age of 55 years (range 45–82). The overall upstage/upgrade rate was 23.6 %. Of the 351 patients, sixty-four (18.2 %) were upstaged to invasive disease and nine-teen (5.4 %) were upgraded to grade 3 DCIS. It is worth noting a rate of 7.9 % of patients with &gt;pT1c and 2.3 % of patients with nodal involvement at the time of surgery. On both univariable and multivariable analysis, no specific variable was found to be a statistically significant predictor for upstaging.</div></div><div><h3>Conclusion</h3><div>Over 23 % of patients with low-risk DCIS may be upgraded or upstaged at resection, especially towards invasive carcinoma (18.2 % of cases were staged to invasive cancer at surgical resection). These data suggest that active surveillance is not warranted in this highly selected group of low-risk DCIS patients. Stricter selection criteria must be considered to ensure appropriate treatment of such patients.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 7","pages":"Article 109716"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143637184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of peritoneal gastric metastasis: An update","authors":"Antoine Mariani ,&nbsp;Evangelia Triantafyllou ,&nbsp;Vahan Kepenekian ,&nbsp;Aziz Zaanan ,&nbsp;Olivier Glehen ,&nbsp;Mehdi Karoui","doi":"10.1016/j.ejso.2025.109731","DOIUrl":"10.1016/j.ejso.2025.109731","url":null,"abstract":"<div><h3>Importance</h3><div>Peritoneal metastases from gastric cancer (PMGC) are associated with poorer median survival and systemic chemotherapy remains the standard of care. This narrative review summarizes the current evidence for medical and surgical treatment of PMGC.</div></div><div><h3>Observations</h3><div>Treatment is moving to local ways of administering chemotherapy, either intraperitoneal normothermic chemotherapy, laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) or even pressurized intraperitoneal aerosol chemotherapy. Furthermore, cytoreductive surgery±HIPEC could also be an alternative in specific situations.</div></div><div><h3>Conclusions</h3><div>and relevance: This review provides an updated summary of existing strategies that can be discussed in the management of patients with PMGC.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 6","pages":"Article 109731"},"PeriodicalIF":3.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}